Rationale, Design, and Implementation of Intensive Risk Factor Treatment in the CREST2 Trial

A subanalysis of patients entered in the CREST2 trial (carotid revascularization and medical management for asymptomatic carotid stenosis) from 2014 to March 23, 2020 was performed. Interim risk factor data were gathered 1618 at baseline follow-up through 24 months analyzing intensive alone compared with plus endarterectomy or transfemoral artery stenting preventing stroke death. The mean low-density lipoprotein level 80 mg/dL, which had significantly improved 67 mg/dL after treatment. systolic blood pressure 140 mm Hg 130 Hg. rigorous approach resulted significant improvements control.